March 07, 2026 12:54 pm (IST)

Make this your homepage

All Finance

Sensex, Nifty tumble as global tensions and Dow selloff rattle Indian markets | Two IAF pilots killed as Su-30MKI fighter jet crashes in Assam | 'Who is the US to permit?': Congress slams Modi govt over Trump administration’s waiver on India’s Russian oil purchase | US makes surprise move: India gets 30-day waiver to buy Russian oil amid global supply crisis | India edge England by 7 runs in thriller to reach T20 World Cup 2026 final | 'Guest of India struck in international waters': Iran furious after US submarine torpedoes IRIS Dena | Bihar's 'Susashan Babu' Nitish Kumar announces exit as CM, set for Rajya Sabha debut | ‘Baseless’: India rejects claims US used its ports to strike Iran | Defiant silence: Iran women’s team refuses anthem days after Khamenei’s death | 'You’ll find out soon': Trump hints at massive retaliation after Riyadh attack, says ‘boots on ground’ may not be needed

Dr Reddy's acquires rights to an investigational anti-cancer agent

India blooms News Service | | Mar 31, 2016, at 07:47 pm

#Raghav Chari # Executive Vice President # Proprietary Products Group # Dr Reddy

Hyderabad, Mar 31 (IBNS) Dr Reddy's Laboratories, an integrated pharmaceutical company, announced on Thursday that it has entered into a licensing agreement with Eisai Company Limited of Japan, by which Dr Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777.

Eisai will develop and market E7777 in Japan and Asia; Dr Reddy's holds the option for rights to develop and market the agent in India, the company said.

In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets.

Raghav Chari, Executive Vice President, Proprietary Products Group, Dr Reddy's Laboratories, said, "E7777 has significant potential as an important component of systemic therapy for cutaneous T-cell lymphoma (CTCL). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.

India
International

Related Images

Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm

Veedol signs former Indian skipper Sourav Ganguly as brand ambassador Jun 29, 2024, at 06:38 am

In Images: Glimpses from Bengali film Fatafati's premiere May 13, 2023, at 08:39 pm